Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - From preclinical studies to a clinical phase II trial

Hanno M. Specht, Norbert Ahrens, Christiane Blankenstein, Thomas Duell, Rainer Fietkau, Udo S. Gaipl, Christine Günther, Sophie Gunther, Gregor Habl, Hubert Hautmann, Matthias Hautmann, Rudolf M. Huber, Michael Molls, Robert Offner, Claus Rödel, Franz Rödel, Martin Schuetz, Stephanie E. Combs, Gabriele Multhoff

Research output: Contribution to journalReview articlepeer-review

84 Scopus citations

Fingerprint

Dive into the research topics of 'Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - From preclinical studies to a clinical phase II trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science